These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16616575)

  • 41. Short-term daily teriparatide in patients with rheumatoid arthritis.
    Kaneko T; Okamura K; Yonemoto Y; Okura C; Suto T; Tachibana M; Tamura Y; Inoue M; Chikuda H
    Mod Rheumatol; 2018 May; 28(3):468-473. PubMed ID: 28805099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Osteoporosis associated with rheumatoid arthritis].
    Kameda H; Takeuchi T
    Nihon Rinsho; 2003 Feb; 61(2):292-8. PubMed ID: 12638224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis: a systematic review.
    Sakthiswary R; Das S
    Curr Drug Targets; 2013 Dec; 14(13):1552-7. PubMed ID: 23848441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis?
    Lescaille G; Coudert AE; Baaroun V; Javelot MJ; Cohen-Solal M; Berdal A; Goudot P; Azérad J; Ruhin B; Descroix V
    J Rheumatol; 2013 Jun; 40(6):781-6. PubMed ID: 23504384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: a systematic review and network meta-analysis.
    Yang Y; Qiu S; Deng L; Tang X; Li X; Wei Q; Fu P
    BMC Nephrol; 2018 Oct; 19(1):269. PubMed ID: 30340537
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
    Güler-Yüksel M; Bijsterbosch J; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Hulsmans HM; de Beus WM; Han KH; Breedveld FC; Dijkmans BA; Allaart CF; Lems WF
    Ann Rheum Dis; 2008 Jun; 67(6):823-8. PubMed ID: 17644545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathogenesis of bone lesions in rheumatoid arthritis.
    Goldring SR; Gravallese EM
    Curr Rheumatol Rep; 2002 Jun; 4(3):226-31. PubMed ID: 12010607
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of bisphosphonates to improve the durability of total joint replacements.
    Shanbhag AS
    J Am Acad Orthop Surg; 2006 Apr; 14(4):215-25. PubMed ID: 16585363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis.
    Richards JS; Cannon GW; Hayden CL; Amdur RL; Lazaro D; Mikuls TR; Reimold AM; Caplan L; Johnson DS; Schwab P; Cherascu BN; Kerr GS
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1864-70. PubMed ID: 22740421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of bone loss induced by aromatase inhibitors.
    Gnant M
    Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New therapeutic agents for the treatment of bone diseases.
    Lipton A
    Expert Opin Biol Ther; 2005 Jun; 5(6):817-32. PubMed ID: 15952912
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How do bisphosphonates affect fracture healing?
    Kates SL; Ackert-Bicknell CL
    Injury; 2016 Jan; 47 Suppl 1(0 1):S65-8. PubMed ID: 26768295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Paricalcitol, a synthetic vitamin D analog: a candidate for combination therapy with biological agents in rheumatoid arthritis.
    Kim TH; Ji JD
    Med Hypotheses; 2010 Dec; 75(6):634-5. PubMed ID: 20736134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging anti-osteoclast therapy for rheumatoid arthritis.
    Tanaka S
    J Orthop Sci; 2018 Sep; 23(5):717-721. PubMed ID: 30075997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RANKL: A therapeutic target for bone destruction in rheumatoid arthritis.
    Tanaka S; Tanaka Y; Ishiguro N; Yamanaka H; Takeuchi T
    Mod Rheumatol; 2018 Jan; 28(1):9-16. PubMed ID: 28880683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study.
    Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Anno S; Koike T
    Rheumatol Int; 2017 Jun; 37(6):999-1005. PubMed ID: 28405825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.
    Fautrel B; Pham T; Mouterde G; Le Loët X; Goupille P; Guillemin F; Ravaud P; Cantagrel A; Dougados M; Puéchal X; Sibilia J; Soubrier M; Mariette X; Combe B; ;
    Joint Bone Spine; 2007 Dec; 74(6):627-37. PubMed ID: 18037319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.